Northwest Therapeutics' DCvax-prostate consists of autologous dendritic cells (DCs) loaded with prostate-specific membrane antigen (PSMA) peptides, administered intravenously. Phase I-II testing, a decade ago, showed clinical benefit and immunological response in some patients. More recently DCvax brain, a product using a similar DC platform showed encouraging Phase I-II results and sipleucel-T, a prostatic acid phosphatase (PAP)-directed DC immunotherapy had positive Phase III results.

OBJECTIVE:

Features of the clinical setting into which a new immunotherapy could be introduced are discussed, to refine a perspective on DCvax-prostate in the context of evolving prostate cancer therapeutics. PSMA-directed therapeutics and immune anticancer technologies are reviewed, and the clinical and immunological correlative testing of DCvax-prostate is discussed.

METHODS:

Clinical and preclinical data from peer-reviewed literature, meetings proceedings and manufacturer-provided information are considered.

CONCLUSION:

DCvax-prostate had encouraging early-phase trial results, but development and testing had stalled. As a more detailed understanding of patient-selection for capacity for anticancer immune response, the quantitation of immunological correlates, and the changing marketplace develop, it is appealing to consider a well tolerated, PSMA-directed autologous dendritic cell therapeutic product. Further clinical trial development of DCvax-prostate is warranted, and required if it is to find a relevant clinical application.

2002-08-01·Current opinion in molecular therapeutics

Technology evaluation: DCVax, Northwest Biotherapeutics.

Article

作者: Knutson, Keith L

DCVax, a dendritic cell-based immunotherapy, is an active immunization platform being developed by Northwest Biotherapeutics for the potential treatment of multiple malignancies, including hormone-refractory metastatic prostate cancer, non-small-cell lung cancer, renal cancer and glioblastoma multiforme. The DCVax platform is tailored to a specific cancer type with either purified tumor-specific antigen or tumor cell extracts derived from patients at the time of resection. Phase I/II clinical trials of DCVax-Prostate have been completed, and phase III clinical trials have recently been initiated. DCVax-Brain is currently undergoing phase II clinical trials, and DCVax-Lung recently received approval from the US FDA for phase I clinical trials.

100 项与 DCVax-Prostate 相关的药物交易

登录后查看更多信息